Chemical formula: C₄₀H₅₃N₇O₅S₂ Molecular mass: 776.03 g/mol PubChem compound: 25151504
Cobicistat is a mechanism-based inhibitor of cytochromes P450 of the CYP3A subfamily. Inhibition of CYP3A-mediated metabolism by cobicistat enhances the systemic exposure of CYP3A substrates, such as darunavir, where bioavailability is limited and half-life is shortened due to CYP3A-dependent metabolism.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| V03AX03 | V Various → V03 All other therapeutic products → V03A All other therapeutic products → V03AX Other therapeutic products | |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| TYBOST Film-coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Cobicistat is an active ingredient of these brands:
United States (US)Australia (AU)Austria (AT)Brazil (BR)
Canada (CA)Croatia (HR)Ecuador (EC)
Estonia (EE)Finland (FI)France (FR)Ireland (IE)Italy (IT)Lithuania (LT)Netherlands (NL)New Zealand (NZ)
Poland (PL)Romania (RO)Spain (ES)United Kingdom (UK)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
